Tradestie Institutional Equity Comparison Engine
RCEL vs PMI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RCEL Overall Edge
RCEL Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avita Medical, Inc. Common Stock (RCEL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RCEL trades at 10.3x Forward P/E with -33.9% operating margin (+53.1% YoY revenue) versus PMI at N/M Forward P/E and -248.1% operating margin (+38.6% YoY). In options structure, RCEL sits in CONSOLIDATION (14th %ile IV; Dealer Gamma Walls on Pro) against PMI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
RCEL
RCEL 10.3x vs PMI N/M Fwd P/E
Growth & Margin Winner
RCEL
Op Margin -33.9% vs -248.1% ยท YoY +53.1% vs +38.6%
Momentum & Technical Winner
RCEL
1Y +304.8% vs +107.2% ยท 52W Pos 84% vs 34%
Options & Structure Winner
RCEL
CONSOLIDATION (14th %ile IV) vs UNCLASSIFIED (N/A IV)
RCEL
NASDAQ
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.99
-4.99% 1D
Market Cap
$533.3M
1M Return
+4.58%
1Y Return
+304.81%
Forward P/E
10.3x
Unified AI Score
45.8 / 100
HOLD
Tech 41.0
Fund 44.0
Flow 67.0
Mom 31.1
PMI
NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap
$17.1M
1M Return
-34.58%
1Y Return
+107.24%
Forward P/E
N/M
Unified AI Score
48.4 / 100
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RCEL +304.81%
PMI +107.24%
Spread: +156.78 pp (RCEL Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RCEL Revenue | PMI Revenue | RCEL Op. Margin | PMI Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -1489.9% | N/A | RCEL |
| FY2019 | $10M | N/A | -466.4% | N/A | RCEL |
| FY2020 | $10M | N/A | -299.2% | N/A | RCEL |
| FY2021 | $30M | N/A | -90.8% | N/A | RCEL |
| FY2022 | $30M | N/A | -79.9% | N/A | RCEL |
| FY2023 | $50M | N/A | -85.1% | N/A | RCEL |
| FY2024 | $60M | $0M | -88.1% | -312.3% | RCEL |
| FY2025 | $70M | $0M | -59.4% | -268.4% | RCEL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RCEL | PMI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $533.3M | $17.1M | Larger Scale | RCEL |
| Trailing P/E Ratio Valuation | 10.3x | 2.9x | Lower Multiple | PMI |
| Forward P/E Ratio Valuation | 10.3x | N/M | Lower Multiple | RCEL |
| Revenue Growth (YoY) Growth | +53.1% | +38.6% | Higher Growth | RCEL |
| Operating Margin (TTM) Profitability | -33.9% | -248.1% | Higher Margin | RCEL |
| Net Profit Margin Profitability | -42.6% | 0.0% | Higher Margin | PMI |
| Return on Equity (ROE) Capital Efficiency | -1746.3% | 0.0% | Higher ROE | PMI |
| 52-Week Range Position Momentum | 84% ($3โ$18) | 34% ($0โ$18) | Stronger Trend | RCEL |
| Beta / 30D Volatility Risk Regime | 1.59ฮฒ ยท 64% Vol | 54.06ฮฒ ยท 134% Vol | Lower Realized Risk | RCEL |
| Unified Institutional Score Composite Signal | 45.8 / 100 (HOLD) | 48.4 / 100 (HOLD) | Higher Composite | PMI |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RCEL vs PMI Buy Guide
RCEL
CONSOLIDATION
16d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
PMI
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RCEL nor PMI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.